Needham & Company LLC began coverage on shares of Novogen (NASDAQ:KZIA – Free Report) in a research note released on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $27.00 price objective on the stock.
KZIA has been the topic of several other research reports. Guggenheim began coverage on shares of Novogen in a report on Wednesday, October 21st. They set a “buy” rating and a $35.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a report on Thursday, October 15th. Canaccord Genuity Group initiated coverage on Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price target for the company. Leerink Partners assumed coverage on Novogen in a research note on Tuesday, October 20th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Novogen in a research note on Thursday, September 10th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.50.
Check Out Our Latest Analysis on KZIA
Novogen Stock Performance
Shares of KZIA stock opened at $8.50 on Friday. The stock’s fifty day moving average price is $10.23 and its 200 day moving average price is $10.48. Novogen has a 1-year low of $4.86 and a 1-year high of $17.40.
About Novogen
Novogen Limited was an Australian biotechnology company that developed novel therapies for cancer. The company focused on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival, with an emphasis on cancers that have limited treatment options.
In 2016, Novogen changed its name to Kazia Therapeutics Limited and continued its oncology research under the Kazia name. Its principal development program became paxalisib, an investigational PI3K/mTOR inhibitor being studied for brain cancers, including glioblastoma and brain metastases.
Featured Articles
- Five stocks we like better than Novogen
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
